#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Epilepsy with myoclonic-atonic seizures Hereditary hypophosphataemic rickets Pulmonary hypertension Infantile spasms Krabbe's disease Cerebral amyloid angiopathy Medullary thyroid cancer Brain stem glioma Skin angiosarcoma Dupuytren's contracture Hypereosinophilic syndrome Mucous membrane pemphigoid Oesophageal adenocarcinoma Palmoplantar pustulosis Fibrosarcoma More trials…

    Learn about Rare Diseases

    Choroid melanoma Behcet’s syndrome – Treatment Ehlers-Danlos syndrome – Life with Disease Hyperoxaluria – Treatment Prolymphocytic leukaemia – Treatment Adrenocortical carcinoma – Basic Information Von Willebrand’s disease – Trials in Disease Shprintzen-Goldberg syndrome – Life with Disease Alveolar rhabdomyosarcoma – Trials in Disease Mucopolysaccharidosis III – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Loperamide Hydrochloride Vx-264 Tiapride HUPERZINE A Gad20-209-Fsp-A4 Ubiquinol ARFOLITIXORIN ANX007 Baclofen Taurine Testosterone Opelconazole Mps-103 Trimetazidine Dihydrochloride Tisagenlecleucel Pyridoxine Hydrochloride Molgramostim Tomligisiran Xenon Escitalopram Oxalate More therapies…

    Learn about Your Condition

    Aortic disorder Choreoathetosis Stem cell transplant Colitis Heart disease congenital Amyloidosis Myocardial infarction Electronic cigarette user Craniotomy Hepatic angiosarcoma Castleman's disease Renal impairment Rheumatoid arthritis Large cell lung cancer stage 0 Meningioma malignant More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Pratia Hematologia Sp. z o.o.

Pratia Hematologia Sp. z o.o.

Uej Trajfnil Khamtbojun 9bi Kslzfblzr 4fthbwq Ptcdrp

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

    Recruiting

    3 1 1
    Investigated Drugs:
    • Teclistamab
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    Czechia France Germany Greece Italy Poland +1

  • Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Topotecan Hydrochloride
    Austria Belgium Czechia Denmark France Germany +5

  • Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

    Recruiting

    3 1 1
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Rituximab
    Czechia France Poland Romania Spain

  • Study of MK-1045 alone or with Tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Tocilizumab
    France Germany Italy Poland Spain

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Finland France +10

  • A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Acalabrutinib
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Zanubrutinib
    Czechia France Germany Italy The Netherlands Poland +3

  • A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elritercept
    • Epoetin Alfa
    Belgium Bulgaria France Germany Greece Hungary +8

  • A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Fluorouracil
    Belgium Denmark France Germany Italy The Netherlands +2

  • A study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer

    Recruiting

    1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • BNT327
    France Italy Poland Spain

  • Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer metastatic
    • Small cell lung cancer
    • Small cell lung cancer extensive stage
    Investigated Drugs:
    • Atezolizumab
    • BNT327
    • Carboplatin
    France Germany Italy The Netherlands Poland Romania +1
1 2 3 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!